BLSM
BLOSSOMHILL THER (BLSM)
NASDAQ
$13.77-$1.07 (-7.21%)
Price as of Nov 13, 2026 1:52 PM EST
  • $471.7M
    Market Cap
  • N/A
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: N/A
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

No data found

No data found

Peers

Statistics

More
Day Range
$14.51
$16.10
$14.84
1-Year Range
$12.35
$26.82
$14.84
Latest Close$14.84
Change
-$1.28 (-8.63%)
Volume256,383
Market Cap$471.7M
Shares Outstanding31.8M
P/E (TTM)-3.30
Diluted EPS (TTM)-$4.49
Enterprise Value$246.8M

Information as of 11/12/2026

Company Profile

BLOSSOMHILL THERAPEUTICS INC
BLOSSOMHILL THERAPEUTICS INC
https://bhtherapeutics.com
$471.7M
Market Cap
-$47.8M
Net Income
Sector: Healthcare
Industry: Biotechnology
10255 Science Center Drive, San Diego, CA, United States, 92121
(858) 732-3880

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.

Key Executives

  • Geoff Oxnard
  • Jingrong Jean Cui
  • Yishan Li
  • Jason A. Keyes
  • Eugene Y. Rui

Current Ownership Distribution

  • Other28.6M (98.43%)
  • Mutual Funds455,565 (1.57%)
  • Institutions0 (0.00%)
  • Insiders0 (0.00%)